Managed Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022 Cytokinetics announced the start of COURAGE-ALS OLE (Clinical Outcomes Using Reldesemtiv on ALSFRS-R… More >>

Today Amylyx announced that Health Canada has approved ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). Clinical data demonstrated a statistically significant and… More >>

• 12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of life • Tofersen also led to robust and sustained reductions… More >>

TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties Tranquis plans to start a Phase 2 trial in ALS by the end of 2022 Tranquis Therapeutics, a clinical stage immuno-neurology… More >>

The findings in Alzheimer disease further elucidated the safety profile of AMX0035, as treatment emergent adverse events in the PEGASUS trial appeared to be largely disease driven. New data from… More >>

Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups after single doses Extending dose observation period from three months (day 85) to six months… More >>

Dear ALS Community, We are writing to let you know that Biogen and Ionis Pharmaceuticals announced topline results from the Phase 1 study of BIIB078/Ionis-C9RX. This asset was an investigational… More >>

Biogen and Ionis Pharmaceuticals today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS). In… More >>